



with eyes
set on the
future

Investment
Innovation
Internationalization
Partnerships
Quality

 bluepharma

Who we are

Bluepharma is a privately owned
portuguese **pharmaceutical group**.

Through the entrepreneurship of its promoters, Bluepharma Group currently comprises 20 innovative companies that cover all stages of the pharmaceutical industry value chain.

Bluepharma's R&D-based strategy allowed to target the most demanding markets.

over
40
Worldwide Territories



more than
120
Worldwide Clients



more than
87%
Export Rate



Bluepharma offers an integrated approach, including innovative research as well as the development, manufacturing and commercialization of medicines. This has proven to be determinant in our differentiation and competitiveness.





On Time
in Full



Reduced
Lead Time



Right First
Time



Lean Six
Sigma

Our integrated approach

Bluepharma offers an integrated approach, providing support on all steps of the product development, **from R&D to market.**

Why work with us



Leading contract developer and manufacturer, with an integrated approach.



Full-scale development projects with a proven track-record in international product launches.



Long-term partnerships, based on time to market, cost-awareness and a result-driven strategy.



R&D Centers and Manufacturing plants in Portugal.



Capability to develop and manufacture high potency products.



High quality standards recognized by several international regulatory authorities.

Where we are

Bluepharma collaborates globally with major pharmaceutical companies through licensing of its own technology or distribution of its own brand.

Our numbers



+750
Employees



+100
Countries



+60
INNs
Produced



+160
End
Customers



+15%
R&D Investment
Over Turnover

Our own brand




109
INNs
Commercialized



11
Therapeutic
Areas





Innovative Solutions

Oromucosal delivery

Oral Thin Films
BlueOS®

Buccal Sprays
BluEase™

Oral Dispersible Tablet

Development of novel and versatile **Oromucosal delivery** formulations, aiming to provide solutions to unmet medical needs through Value Added Medicines.

OSD Fixed-Dose Combinations

Development of advanced formulations that aim the modulation of the release profile, overcome barriers such as incompatibilities between molecules and increase of the stability, including **multi-layer tablets**, **micro tablets**, **capsule-in-capsule** and **Hot Melt Extrusion** technologies.

Complex Steriles

Lipid nanoparticles (LNP)

Polymer-based microparticles

Development of **Complex Sterile** formulations, that offer unique advantages and solve major challenges of conventional oral or parenteral drug delivery systems.



Research and development of novel **therapeutic strategies for cancer**. The lead compound, **Redaporfin**, has been granted Orphan Drug Designation (ODD) from both EMA and FDA and achieved successful results from its phase I-IIa clinical trial in advanced head and neck cancer.



Research and development of innovative **targeted nanoparticles (PEGASEMP®)** capable of targeting two distinct cell populations in the tumor: the cancer cells and the blood vessels that nurture the tumor. Orphan Drug Designation (ODD) has been granted to PEGASEMP® from both EMA and FDA. PEGASEMP® has completed a formal non-clinical program and preparation of entry-into-humans study is undergoing.

+15%

R&D INVESTMENT
OVER TURNOVER

Our Value

Bluepharma's aim
is to **create value**
through innovation.

This is achieved in dedicated R&D facilities that offer services ranging from the formulation and analytical development to the design of novel delivery platforms, as well as dedicated facilities for high potency drugs.



Holding
Holding



Indústria
Industry



Inovação
Innovation

inovblue



Cuidados de Saúde
Healthcare



Serviços
Services

Lacius Consultoria

Astrum

Why Bluepharma?



Flexible Business Models



International Regulatory Expertise



Global Quality Certifications



Extensive and Differentiated Portfolio

Bluepharma's facilities are
certified/approved by:

- Infarmed/EMA (European Union)
- US FDA (2009, 2012, 2014, 2016, 2019)
- SFDA (Kingdom of Saudi Arabia)
- MFDS (South Korea)
- MSHP (Ivory Coast)
- MOH (Libya)
- TMMDA (Turkey)

We are registered in Iraq, Taiwan,
Jordan, UAE, Kurdistan, Vietnam,
Bahrain and Oman.



For business inquiries:
business@bluepharma.pt

Coimbra · PORTUGAL

Tel. +351 239 800 300

www.bluepharmagroup.com

